A new analysis of data from the phase 3 STEP (semaglutide treatment effect in people with obesity) trials shows that adults using Wegovy for obesity treatment were more likely to discontinue or reduce the intensity of their antihypertensive and lipid-l…
Recent research highlights a trend of high discontinuation rates among patients using glucagon-like peptide-1 receptor agonists for Type 2 diabetes and weight loss.
As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
A new study from the Department of Veteran Affairs, published in Nature Medicine, found that GLP-1 weight loss drugs including Mounjaro, Ozempic, Wegovy and Zepbound, may offer benefits beyond weight loss — the latest in a growing body of research legi…
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study.
Insurers and self-funded employers are making significant changes to their GLP-1 drug coverage policies in 2025, reflecting the financial and operational challenges posed by the high-cost medications.
On Dec. 23, the FDA approved Hikma Pharmaceuticals’ liraglutide injection, a generic version of Novo Nordisk’s Victoza.
In early October, the FDA announced that the two-year shortages of Mounjaro and Zepbound were resolved. After pushback from compounding pharmacies, the agency reaffirmed the decision on Dec. 19.
The prices for some GLP-1s have dropped significantly in recent years for individuals covered by Medicare and commercial insurance, according to a November report from HHS.
A preprint study confirmed an association between Ozempic’s active ingredient and an increased — but overall low — risk of vision loss.
